France's HRA Pharma SA is looking to sharpen its focus on expansion in the global consumer healthcare market by shifting its orphan drug portfolio into a newly-created affiliate company.
HRA Pharma Rare Diseases will be tasked with the development of its portfolio of drugs that address Cushing’s Syndrome (Metopirone,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?